[ad_1] Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank of America analyst Geoff Meacham has been very bullish about the opportunity, which he calls “unprecedented” given the prevalence …
Read More »Tag Archives: Regeneron Pharmaceuticals Inc
4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
[ad_1] Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of …
Read More »Cramer’s week ahead: Earnings season kicks off after JPMorgan Healthcare Conference
[ad_1] CNBC’s Jim Cramer on Friday told investors what to watch for on Wall Street next week, highlighting JPMorgan‘s market-moving health-care conference in San Francisco. Taking place from Monday to Thursday, the conference is one of the year’s largest gatherings of major industry CEOs where they reveal earnings guidance and …
Read More »Oprah’s flip on weight loss drugs is a sign of what’s to come for the ‘Ozempic trade’ in 2024
[ad_1] For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed …
Read More »If you can’t build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
[ad_1] Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by …
Read More »